Page 4 - Barry Ticho News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) announced its earnings results on Monday. The company reported ($0.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.06), MarketWatch Earnings reports. Stoke Therapeutics had a negative net margin of 679.83% and a negative return on equity of 47.86%. Stoke Therapeutics Trading […]

HC Wainwright reaffirmed their buy rating on shares of Stoke Therapeutics (NASDAQ:STOK – Free Report) in a research note released on Monday morning, Benzinga reports. The brokerage currently has a $35.00 target price on the stock. STOK has been the subject of several other reports. Cantor Fitzgerald upped their target price on shares of Stoke […]

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the nine research firms that are covering the company, Marketbeat reports. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among […]

Stoke Therapeutics, Inc. (NASDAQ:STOK – Get Free Report) rose 7.2% during mid-day trading on Wednesday . The stock traded as high as $11.51 and last traded at $11.45. Approximately 51,871 shares were traded during trading, a decline of 82% from the average daily volume of 281,584 shares. The stock had previously closed at $10.68. Analyst […]

Stoke Therapeutics, Inc. (NASDAQ:STOK – Free Report) – Equities researchers at Cantor Fitzgerald issued their FY2024 earnings per share (EPS) estimates for shares of Stoke Therapeutics in a note issued to investors on Tuesday, July 11th. Cantor Fitzgerald analyst C. Duncan expects that the company will earn ($2.34) per share for the year. The consensus […]